The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies. The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:eLife
Autors principals: Joseph, James D, Darimont, Beatrice, Zhou, Wei, Arrazate, Alfonso, Young, Amy, Ingalla, Ellen, Walter, Kimberly, Blake, Robert A, Nonomiya, Jim, Guan, Zhengyu, Kategaya, Lorna, Govek, Steven P, Lai, Andiliy G, Kahraman, Mehmet, Brigham, Dan, Sensintaffar, John, Lu, Nhin, Shao, Gang, Qian, Jing, Grillot, Kate, Moon, Michael, Prudente, Rene, Bischoff, Eric, Lee, Kyoung-Jin, Bonnefous, Celine, Douglas, Karensa L, Julien, Jackaline D, Nagasawa, Johnny Y, Aparicio, Anna, Kaufman, Josh, Haley, Benjamin, Giltnane, Jennifer M, Wertz, Ingrid E, Lackner, Mark R, Nannini, Michelle A, Sampath, Deepak, Schwarz, Luis, Manning, Henry Charles, Tantawy, Mohammed Noor, Arteaga, Carlos L, Heyman, Richard A, Rix, Peter J, Friedman, Lori, Smith, Nicholas D, Metcalfe, Ciara, Hager, Jeffrey H
Format: Artigo
Idioma:Inglês
Publicat: eLife Sciences Publications, Ltd 2016
Matèries:
Cancer Biology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4961458/
https://ncbi.nlm.nih.gov/pubmed/27410477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.15828
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars